Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage
Marco Ladetto(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Corrado Tarella(European Institute of Oncology), Mario Boccadoro(University of Turin), Vincenzo Callea(Azienda Ospedaliero Universitaria San Giovanni Battista), Alessandro Pileri(Azienda USL di Bologna), Attilio Olivieri(Ospedali Riuniti di Ancona), Delia Rota Scalabrini(Fondazione Piemontese per la Ricerca sul Cancro Onlus), Francesco Di Raimondo(University of Catania), Sergio Cortelazzo(Azienda Ospedaliero-Universitaria delle Marche), Paolo Corradini(Gruppo di Ricerca Geriatrica), Alessandro Rambaldi(Ospedale Papa Giovanni XXIII), Fabio Benedetti(Azienda Ospedaliera Universitaria Integrata Verona), Ignazio Majolino, Vincenzo Pavone, Caterina Patti(Ospedale Vincenzo Cervello), Anna Marina Liberati(University of Perugia), Alessandra Tucci(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Alessandro Levis(San Antonio College), Alessandro Pulsoni(Ospedale Santa Maria Goretti), Roberto Passera(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Federica De Marco(Istituto di Ematologia di Bologna), Maurizio Musso(La Maddalena), Enrico Pogliani(Azienda Ospedaliera San Gerardo), Umberto Vitolo(Candiolo Cancer Institute), Alessandro M. Gianni(University of Milan), Andrea Gallamini(Centre Antoine Lacassagne)
Cited by 253
Related Papers
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2015|920